CYTK
CYTK
NASDAQ · Biotechnology

Cytokinetics Inc

$53.69
-1.86 (-3.35%)
As of Nov 7, 1:22 AM ET ·
Financial Highlights (FY 2026)
Revenue
103.64M
Net Income
-924,100,261
Gross Margin
—
Profit Margin
-891.6%
Rev Growth
-2.4%
D/E Ratio
0.59
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 103.64M 106.16M 617.31M 631.19M
Gross Profit — — 257.41M 263.20M
Operating Income -863,494,089 -796,010,119 179.75M 183.04M
Net Income -924,100,261 -851,879,785 113.32M 141.95M
Gross Margin — — 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Rev Growth -2.4% -2.4% +3.9% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.41B 1.41B 602.04M 772.62M
Total Equity 2.39B 2.39B 2.97B 3.11B
D/E Ratio 0.59 0.59 0.20 0.25
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -851,608,225 -828,667,227 314.99M 272.50M
Free Cash Flow — — 143.60M 140.08M